|
|
|
|
|
05.12.25 - 12:03
|
Immatics Announces $125 Million Underwritten Offering (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $125 million. The offering is expected to close on December 8, 2025, subject to customary closing conditions. ...
|
|
|
|
|
|
|
|
|
27.10.25 - 12:03
|
Immatics Appoints Amie Krause as Chief People Officer (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer (“CPO”) effective October 27, 2025. Ms. Krause brings more than 20 years of experience in shaping culture, leading organizational growth and aligning talent with business strategy, including across global biopharmaceutical companies. In this newly established role, she will lead Immatics' human resources, focusing on organizational development and operations as the company transitions to commercial stage.“As we enter our next phase of transforming into a commercial-stage enterprise, we are delighted to welcome Amie. Her experience in building high-performing teams as well as enhancing organizational excellence and efficiency will help position us for continued success as we strengthen our global leadership i...
|
|
|
|
|
|
|
01.10.25 - 13:03
|
Immatics Appoints Venkat Ramanan as Chief Financial Officer (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer (“CFO”), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos Therapeutics, a Novartis company, where he served as CFO. He will succeed Immatics' current CFO, Arnd Christ.“We are thrilled to welcome Venkat to Immatics as an accomplished and passionate biopharmaceutical leader. His extensive experience will be instrumental in enabling us to continue to advance our PR...
|
|
|
|
|
|
|
|
|
|
|
|
|
31.05.25 - 14:03
|
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma (GlobeNewswire EN)
|
|
|
Stafford, Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma. The longer follow-up of patients demonstrates a consistent and favorable tolerability profile as well as durable responses with a confirmed ORR of 56%. In addition, the Company provided details from a Trial in Progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor....
|
|
|
|
|
23.04.25 - 16:03
|
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois....
|
|
|
|
|
27.03.25 - 12:03
|
Immatics Announces Full Year 2024 Financial Results and Business Update (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
